Cheng Cai Tang
Overview
Explore the profile of Cheng Cai Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urva S, Levine J, Schneck K, Tang C
Curr Med Res Opin
. 2024 Feb;
40(4):567-574.
PMID: 38407177
Objective: To evaluate the efficacy endpoints of HbA1c and body weight loss after switching from the GLP-1 receptor agonists, semaglutide or dulaglutide, to treatment with the GIP/GLP-1 receptor agonist (RA)...
2.
Tang C, Lim J, Shen Loo L, Jung H, Konig M, Tham L
J Clin Pharmacol
. 2023 Oct;
64(2):215-226.
PMID: 37853524
Dulaglutide 3.0 and 4.5 mg weekly doses were approved for additional glycemic control in adult patients with type 2 diabetes inadequately controlled with metformin and 0.75 or 1.5 mg weekly...
3.
Tham L, Pantalone K, Dungan K, Munir K, Tang C, Konig M, et al.
Diabetes Obes Metab
. 2021 Oct;
24(2):302-311.
PMID: 34697882
Aim: To evaluate HbA1c and body weight changes when semaglutide 0.5- or 1.0-mg once-weekly (QW) is switched to dulaglutide 3.0- or 4.5-mg QW via exposure-response modelling. Methods: HbA1c and body...
4.
Tseng S, Poh Lim C, Chen Q, Tang C, Kong S, Ho P
Antimicrob Agents Chemother
. 2018 Jan;
62(4).
PMID: 29358290
Bacterial sepsis is a major cause of morbidity and mortality in neonates, especially those involving methicillin-resistant (MRSA). Guidelines by the Infectious Diseases Society of America recommend the vancomycin 24-h area...
5.
Kim H, Brooks K, Tang C, Wakim P, Blake M, Brooks S, et al.
Clin Pharmacol Ther
. 2017 Nov;
104(2):364-373.
PMID: 29134648
Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a...
6.
McColm J, Hu L, Womack T, Tang C, Chiang A
J Bone Miner Res
. 2013 Sep;
29(4):935-43.
PMID: 23996473
Two clinical studies were conducted to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses (intravenous [iv] and subcutaneous [sc]) of blosozumab in postmenopausal women,...
7.
Cui Y, Guo X, Zhang D, Tham L, Tang C, Mace K, et al.
J Diabetes
. 2013 Jan;
5(2):127-35.
PMID: 23332026
Background: This open-label, single-period study assessed the pharmacokinetics, safety, tolerability, and pharmacodynamics of exenatide once weekly (q.w.), following single and multiple weekly subcutaneous (s.c.) injections in native Chinese patients with...
8.
Kulkarni R, Yumibe N, Wang Z, Zhang X, Tang C, Ruterbories K, et al.
J Pharm Sci
. 2012 Aug;
101(11):4327-36.
PMID: 22899546
The utility of pigs as preclinical animals for pharmaceutical development was assessed by evaluating the pharmacokinetics and pharmacodynamics of glipizide (Glucotrol®) following oral administration of immediate-release (IR) and modified-release (MR)...